NCT01720836View on ClinicalTrials.gov

Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2012

Primary Completion Date

October 31, 2027

Study Completion Date

October 31, 2032

Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
BIOLOGICAL

Vaccine + PolyICLC

The vaccine will consist of 100 micrograms of MUC1 100mer peptide dissolved in 50 micro-liters of sterile saline, admixed with 500 micrograms of Hiltonol® in 250 microliters volume, for a total injection volume of 300 microliters.

Trial Locations (1)

15232

RECRUITING

UPMC Hillman Cancer Center, Pittsburgh

All Listed Sponsors
lead

Olivera Finn

OTHER